Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $645K of LYCA (indirect holdings)
Venrock Healthcare Capital Partners III, L.P. purchased 25,004 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $25.78 ($25.23–$26.86, $0.64M total) across 5 trades over 2026-10-28 to 2026-10-30. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed purchase is modest and unlikely to move the stock significantly, but it adds a positive data point for LYCA.
Market read
A small insider buy that provides a slight bullish cue for LYCA but limited overall market relevance.
What to watch
Potential upcoming clinical data could be the real driver behind the insider interest.
Background
Form 4 filings disclose insider transactions; investors watch them for clues on management confidence.
Ticker impact
Venrock Healthcare Capital Partners III purchased 25,004 shares of LYCA for $645K, increasing its indirect stake to 6,850,237 shares.
likely upward pressure as market prices in the insider buy
The transaction is a primary Form 4 filing, but the amount is modest ($645K) for a micro‑cap biotech, limiting material impact.
Market effects
Minor signal for the biotech sector; no broader industry impact.
Limited to US markets where LYCA trades.
Low
Counterpoint
The purchase may be routine portfolio rebalancing rather than a strong endorsement.
Key entities
- companyLycia Therapeutics, Inc.
US‑listed biotech developing therapies for rare diseases.
- investorVenrock Healthcare Capital Partners III, L.P.
Venture capital fund making an indirect purchase of LYCA shares.